In a study published in Scientific Reports, researchers highlighted structural and functional brain differences among those who suffer menstrual-related migraine (MRM) and pure menstrual migraine (PMM).
In a study published in Scientific Reports, researchers highlighted structural and functional brain differences among those who suffer menstrual-related migraine (MRM) and pure menstrual migraine (PMM).
The International Classification of Headache Disorders III beta notes menstrual migraines (MM) are associated with the menses and MM is divided into 2 subcategories: MRM and PMM. “Unlike PMM, MRM involves migraine attacks that occur outside of the menstrual cycle,” authors wrote, while “an epidemiological survey showed that 21% of women with migraine experience MM, and approximately 66% experience MRM.”
It is generally accepted that an inflammatory response may be a possible mechanism for the pathogenesis of MM. However, differences in attack frequency may mean PMM and MRM have different effects on the brain’s structure and function.
Researchers used resting-state functional MRI (rsfMRI) and structural magnetic resonance imaging (sMRI) to evaluate differences between 32 patients with MRM and 16 patients with PMM. All patients were recruited between June 2015 and August 2018.
Of those with MRM, mean (SD) age was 33.41 (6.23) years, while mean age of those with PMM was 31.75 (7.85) years. All patients stopped prophylactic medications for migraine 4 weeks before the examination and did not experience a typical migraine attack for at least 1 week prior to the MRI.
Although no differences in migraine duration or intensity were reported between the 2 cohorts, those with MRM exhibited a significantly higher migraine frequency compared with those with PMM (P <.001). Patients also did not exhibit differences in grey matter volume.
Investigators applied voxel-based morphometry (VBM) on sMRI, and both the amplitude of low-frequency fluctuations (ALFF) and regional homogeneity (ReHo) in rsfMRI were calculated. ALFF demonstrates the intensity of regional spontaneous neural activity while ReHo can demonstrate neural concordance.
Researchers found:
The DLPFC and mPFC pertain to the frontal cortex, one of the more prominent regions associated with brain activity in migraineurs, researchers explained. Because of this, “we speculate the lower level of regional functional neural activity in the DLPFC and mPFC of MRM patients may influence the inhibitory control of pain perception and mediation of additional attacks of migraine outside of the menstrual cycle,” authors wrote.
A relatively small sample size, lack of hormonal testing, and absence of a healthy control group mark limitations to the study. Future longitudinal fMRI studies ought to be carried out to establish and confirm the current findings, researchers concluded.
Reference
Xu T, Zhang Y, Wang C. Brain structural and functional differences between pure menstrual migraine and menstrually-related migraine. Sci Rep. Published online October 5, 2020. doi: 10.1038/s41598-020-73399-0
Optimizing Episodic Migraine Care: ACP’s Latest Treatment Guidance
February 3rd 2025With historical data showing migraine to be underdiagnosed and undertreated, new guidance from the American College of Physicians (ACP) encompasses 3 recommendations on treating episodic migraine in adult patients in the outpatient setting.
Read More
Update on Migraine Patient Care Challenges During the Pandemic
October 5th 2021Migraines plague some 35 million Americans, the majority of them women in their 30s and 40s, and disabling pain and symptoms are linked to lost productivity at work, school, and home. On this episode of Managed Care Cast, we bring you an excerpt of an interview with a headache specialist about the extra challenges for patients and providers during the pandemic.
Listen
Care for Migraine Insufficient in Germany, Online Survey Finds
March 25th 2022An online survey of migraineurs in Germany aimed to evaluate their most pressing unmet needs, with data collected on socioeconomic background, medical care experience, acute medication use, and migraine prophylaxis use and experience.
Read More
CGRP Inhibitors: A Promising New Class of Drugs for Migraine
November 14th 2018This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss calcitonin gene-related peptide (CGRP) inhibitors, an emerging therapy for the condition, which affects 39 million people in the United States.
Listen